Rituximab therapy in nephrotic syndrome due to AH amyloidosis.
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.
Katoh
Nagaaki
N
Matsuda
Masayuki
M
Miyazaki
Daigo
D
Gono
Takahisa
T
Yazaki
Masahide
M
Ikeda
Shu-Ichi
S
D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy* / Q000209:etiology; D000906:Antibodies / Q000235:genetics / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D054219:Neoplasms, Plasma Cell / Q000150:complications / Q000188:drug therapy; D009404:Nephrotic Syndrome / Q000188:drug therapy / Q000209:etiology; D000069283:Rituximab
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab